Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Takeda Pharmaceutical has set its FY 2024 guidance at 2.770-2.770 EPS.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Takeda Pharmaceutical Price Performance
Takeda Pharmaceutical stock traded down $0.06 during mid-day trading on Thursday, hitting $13.80. The stock had a trading volume of 811,755 shares, compared to its average volume of 1,858,790. The firm has a market capitalization of $43.89 billion, a P/E ratio of 26.04, a P/E/G ratio of 0.27 and a beta of 0.54. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm's 50 day moving average is $14.61 and its 200 day moving average is $13.77. Takeda Pharmaceutical has a one year low of $12.57 and a one year high of $15.08.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
